GlassScriptPhysician profile
Alice D Thomas
NPI 1164965695
$1,339.18
in general payments reported to CMS, 2019-2025
17 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $112 · 2023: $386 · 2024: $324 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Education: $18.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.31 |
| Education | $18.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $188.83 | 2024-2025 | |
| Nxstage Medical, INC. | $188.45 | 2022-2023 | Liberty Select Cycler, Nxstage System One |
| Amgen INC. | $153.94 | 2024-2025 | Tavneos, Krystexxa |
| Fresenius USA Marketing, INC. | $119.74 | 2023-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $116.31 | 2023 | |
| Kyowa Kirin, INC. | $110.41 | 2025 | |
| Vifor Pharma, INC. | $85.31 | 2023 | Veltassa |
| Novo Nordisk INC | $58.94 | 2024 | Rivfloza |
| Alexion Pharmaceuticals, INC. | $51.98 | 2024 | Ultomiris |
| Calliditas Therapeutics US INC. | $50.50 | 2024-2025 | Tarpeyo |
| Ardelyx, INC. | $48.37 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $37.46 | 2023-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.30 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $32.49 | 2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $25.00 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $18.38 | 2023 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $17.77 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.